Explore the full record of transactions filed by Werner Milton H., Chairman & CEO. Insider active across 2 companies, notably Inhibikase Therapeutics, Inc.. Aggregated, 10 disclosures have been published. Total volume traded: €72k. The latest transaction was filed on 27 May 2022 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Milton H. Werner is the President and CEO of Inhibikase Therapeutics, Inc. He leads the company with a strategic vision, overseeing operations and research and development initiatives. Milton is responsible for implementing corporate strategies and managing stakeholder relationships. His experience in the biopharmaceutical sector is a valuable asset for the leadership of Inhibikase.